Literature DB >> 17965842

[Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?].

G von Wichert1, T Seufferlein.   

Abstract

Surgical therapy of any malignancy always attempts the complete removal of a cancer from the organism. An adjuvant chemotherapy has the goal to remove remaining tumor-cells, to prevent recurrence of the disease and to improve long term survival. Within the last years there has been a substantial improvement in prognosis due to multi-modal therapeutic regimens including combination-chemo-therapy and innovative radiation-protocols. This review aims to present and to critically review current concepts in the treatment of selected tumors of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965842     DOI: 10.1007/s00108-007-1974-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

Review 1.  Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy.

Authors:  Y Fong
Journal:  Adv Surg       Date:  2000

2.  Chemotherapy in gastric cancer: a review and updated meta-analysis.

Authors:  Karl-Gunnar Janunger; Larsolof Hafström; Bengt Glimelius
Journal:  Eur J Surg       Date:  2002

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

Authors:  M L Rothenberg; N J Meropol; E A Poplin; E Van Cutsem; S Wadler
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 5.  Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

Authors:  Chris J Twelves
Journal:  Clin Colorectal Cancer       Date:  2006-11       Impact factor: 4.481

6.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

7.  OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

Authors:  Graeme J Poston; René Adam; Steven Alberts; Steven Curley; Juan Figueras; Daniel Haller; Francis Kunstlinger; Gilles Mentha; Bernard Nordlinger; Yehuda Patt; John Primrose; Mark Roh; Philippe Rougier; Theo Ruers; Hans Joachim Schmoll; Carlos Valls; Nick Jean-Nicolas Vauthey; Marleen Cornelis; James P Kahan
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

8.  Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.

Authors:  Jacek A Kopec; Greg Yothers; Patricia A Ganz; Stephanie R Land; Reena S Cecchini; H Samuel Wieand; Barry C Lembersky; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

9.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

10.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.